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Many safe and effective severe acute respiratory syndrome coronavirus 2 (SARS- CoV- 2) vaccinations dramatically re-
duce risks of coronavirus disease 2019 (COVID- 19) complications and deaths. We aimed to describe cases of SARS- 
CoV- 2 infection among patients with chronic liver disease (CLD) and liver transplant (LT) recipients with at least one 
prior COVID- 19 vaccine dose. The SECURE- Liver and COVID- Hep international reporting registries were used to 
identify laboratory- confirmed COVID- 19 in CLD and LT patients who received a COVID- 19 vaccination. Of the 
342 cases of lab- confirmed SARS- CoV- 2 infections in the era after vaccine licensing, 40 patients (21 with CLD and 
19 with LT) had at least one prior COVID- 19 vaccination, including 12 who were fully vaccinated (≥2  weeks after 
second dose). Of the 21 patients with CLD (90% with cirrhosis), 7 (33%) were hospitalized, 1 (5%) was admitted to 
the intensive care unit (ICU), and 0 died. In the LT cohort (n  =  19), there were 6 hospitalizations (32%), includ-
ing 3 (16%) resulting in mechanical ventilation and 2 (11%) resulting in death. All three cases of severe COVID- 19 
 occurred in patients who had a single vaccine dose within the last 1- 2 weeks. In contemporary patients with CLD, 
rates of symptomatic infection, hospitalization, ICU admission, invasive ventilation, and death were numerically higher 
in unvaccinated individuals. Conclusion: This case series demonstrates the potential for COVID- 19 infections among 
patients with CLD and LT recipients who had received the COVID- 19 vaccination. Vaccination against SARS- CoV- 2 
appears to result in favorable outcomes as attested by the absence of mechanical ventilation, ICU, or death among fully 
vaccinated patients. (Hepatology Communications 2021;0:1-9).
Since the onset of the coronavirus disease 2019 (COVID- 19) pandemic, we have learned much about the sequelae of COVID- 19 in patients 
with liver disease.(1) Patients with decompensated 
cirrhosis are at increased risk of hospitalization, 
intensive care unit (ICU) admission, and death from 
COVID- 19.(2- 4) Although liver transplant (LT) recip-
ients may not be at higher risk of COVID- 19 mor-
tality,(5,6) some data suggest that these patients might 
have an increased risk of severe acute respiratory 
Abbreviations: CLD, chronic liver disease; COVID- 19, coronavirus disease 2019; GI, gastrointestinal; ICU, intensive care unit; LT, liver 
transplant; MMF, mycophenolate mofetil; mRNA, messenger RNA; SARS- CoV- 2, severe acute respiratory syndrome coronavirus 2.
Received August 12, 2021; accepted October 10, 2021.
Additional Supporting Information may be found at onlinelibrary.wiley.com/doi/10.1002/hep4.1853/suppinfo.
*These authors contributed equally to this work.
Supported by the Wellcome Trust (Clinical Research Training Fellowship), American Association for the Study of Liver Diseases (Advanced/
Transplant Hepatology Award), and National Institutes of Health Clinical Center (T32 DK007634).
© 2021 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver 
Diseases. This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep4.1853
Potential conflict of interest: Dr. Dalekos advises and received grants from Pfizer, Genkyotex, Novartis, and Sobi. He received grants from AbbVie 
and Gilead. Dr. Barritt consults for Target RWE.
Hepatology CommuniCations, month 2021MOON ET AL.
2
syndrome coronavirus 2 (SARS- CoV- 2) infection.(7) 
Meanwhile, vaccine development has progressed at 
a rapid rate, and vaccine rollouts have tended to pri-
oritize vulnerable patients, including immunocom-
promised patients.(8) While the endorsement and 
potential value of SARS- CoV- 2 vaccination is well- 
established in patients with liver disease,(9- 11) more 
data are needed on vaccine response and sequelae of 
postvaccine infections in patients with chronic liver 
disease (CLD) and LT recipients.(12)
There is an excellent immune response to the 
SARS- CoV- 2 vaccination in the general popula-
tion; in vaccinated individuals, complications of 
COVID- 19, including ICU admission and death, are 
incredibly rare.(13- 16) However, vaccine immunogenic-
ity may not be as robust for immunocompromised or 
immunosuppressed patients. Patients with advanced 
liver disease have deficiencies in innate and humoral 
immunity, referred to as cirrhosis- associated immune 
dysfunction.(17,18) Similarly, LT recipients require 
immunosuppressant medications and have blunted 
antibody responses following influenza, hepatitis A, 
hepatitis B, and pneumococcal vaccinations.(19- 22) 
Early data suggest that the antibody response to the 
SARS- CoV- 2 vaccination is attenuated in CLD(23) 
and solid organ recipients.(24,25) However, real- world 
data are still lacking on the patterns and outcomes of 
postvaccination infections in patients with CLD and 
LT recipients.
We used data from two large international registries 
to describe cases of laboratory- confirmed COVID- 19 
among patients with CLD and LT recipients who had 
received vaccination against SARS- CoV- 2.
Patients and Methods
We established an online reporting system for cases 
of laboratory- confirmed SARS- CoV- 2 in patients 
with CLD or prior LT. For this study, data were col-
lected between March 5, 2021, and August 2, 2021 
(era after vaccine licensing), through two collabo-
rating registries (SECURE- Liver supported by the 
American Association for the Study of Liver Diseases 
and COVID- Hep.net supported by the European 
Association for the Study of the Liver). These regis-
tries were coordinated from the University of North 
Carolina (United States) and the University of Oxford 
(United Kingdom). Given that all data submitted to 
these registries were de- identified, both the University 
of Oxford Clinical Trials and Research Governance 
and the University of North Carolina Office of 
Human Research Ethics deemed that this project was 
not human research and did not require formal insti-
tutional review board approval.
As previously described,(2,5) clinicians were 
invited to submit online case report forms provid-
ing de- identified clinical information on cases of 
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laboratory- confirmed SARS- Cov- 2 in patients with 
prior LT or CLD. Case report forms included demo-
graphics, liver disease etiology and severity, SARS- 
Cov- 2 vaccination details, and COVID- 19 outcomes, 
including hospitalization, ICU stay, and death. 
Clinicians were instructed to submit forms after 
patients had COVID- 19 for a long enough duration 
to experience recovery from COVID- 19 or death. 
Here we describe the cases of SARS- CoV- 2 infection 
among patients with at least one prior COVID- 19 
vaccine dose compared with contemporary (i.e., sub-
mitted March 5, 2021, to August 2, 2021) unvacci-
nated patients with CLD and prior LT.
Results
A total of 342 cases of lab- confirmed SARS- 
CoV- 2 infection among patients with CLD and 
prior LT were submitted to SECURE- Liver and 
COVID- Hep 2.0 from March 5, 2021, and August 
2, 2021. Among these, 40 (12%) patients (n = 21 with 
CLD, n = 19 with LT) had at least one prior SARS- 
CoV- 2 vaccination, 14 had received both doses (all 
received the same type of vaccine for both doses), and 
12 occurred ≥2 weeks after the second vaccine dose 
(Fig. 1). Characteristics of CLD and LT cases are 
found in Tables 1 and 2, respectively, and the descrip-
tion of vaccinations received are shown in Fig. 1.
CoViD- 19 in patients WitH ClD 
WitH ≥1 VaCCine Dose VeRsus 
unVaCCinateD
In patients with CLD who received at least one vac-
cination (n = 21), the median age was 59 years (range 
28- 72), 67% were male, and cases were from North 
America (n = 10, 45%), India (n = 6, 27%), the United 
Kingdom (n = 2, 9%), Turkey (n = 1, 5%), Indonesia 
(n = 1, 5%), and Greece (n = 1, 5%) (Table 1). The most 
common CLD etiology reported was nonalcoholic 
fatty liver disease (n  =  7, 33%), and 90% of patients 
Fig. 1. SARS- CoV- 2 infection after COVID- 19 vaccination in patients with liver disease and transplantation.
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had cirrhosis (Child Pugh A/B/C, 63%/32%/5%). 
SARS- CoV- 2 infection was diagnosed after one vac-
cine dose in 13 (62%) and after two doses in 8 (38%). 
Viral vector vaccines (Oxford- AstraZeneca, CanSino) 
were received by 13 (62%), messenger RNA (mRNA) 
vaccines (Pfizer- BioNTech, Moderna) by 5 (24%), 
and inactivated vaccines (Bharat Biotech, Sinovac) by 
3 (14%). Among those who received a single vaccine 
dose, the median time from vaccination to infection 
was 3 weeks (range 0- 8), and for those who received 
both doses, the median time from the second dose to 
infection was 3  weeks (range 1- 8). Regarding symp-
toms at presentation, 11 (57%) had respiratory symp-
toms, 1 (5%) had gastrointestinal (GI) symptoms, 1 
(5%) had GI and respiratory symptoms, and 8 (38%) 
reported no GI or respiratory symptoms (Table 3). 
Of these 21 patients who received prior vaccination, 
7 (33%) were hospitalized, 1 (5%) was admitted to 
the ICU, 0 required invasive ventilation, and 0 died. 
Among patients with cirrhosis (n  =  19), 9 (47%) 
developed a new decompensating event (8 new/wors-
ening ascites, 7 hepatic encephalopathy, 4 spontaneous 
bacterial peritonitis), including 5 patients who were 
fully vaccinated (≥2 weeks after second dose).
In comparison, among the 225 unvaccinated 
patients with CLD with COVID- 19 (median age 59 
years, 62% male, 72% cirrhosis, Child- Pugh A/B/C 
47%/31%/22%), 185 (76%) had respiratory and/or 
GI symptoms from COVID- 19 compared with 57 
(24%) who did not endorse GI or respiratory symp-
toms. Of these unvaccinated CLD cases, 162 (72%) 
were hospitalized, 20 (9%) were admitted to the ICU, 
12 (5%) required invasive ventilation, and 18 (8%) 
died, primarily from COVID- 19 lung disease (n = 11 
of 18, 61%) (Table 3). Similarly, rates of symptomatic 
infection, hospitalization, ICU admission, invasive ven-
tilation, and death were numerically higher in unvac-
cinated compared to vaccinated patients with cirrhosis 
(Table 3).
CoViD- 19 in lt ReCipients 
WitH ≥1 VaCCine Dose VeRsus 
unVaCCinateD
Among LT recipients who received at least one vac-
cination (n = 19), the median age was 60 years (range 
32- 79), 58% were male, and most were from North 
America (n  =  14, 74%) followed by Turkey (n  =  2, 
11%), India (n  =  2, 11%), and the United Kingdom 
(n = 1, 5%) (Table 2). The median time from LT to 
infection was 4 years (range 1- 24), and the most com-
mon immunosuppression regimen prior to diagnosis 
was tacrolimus monotherapy (n  =  8, 42%). A total 
of 7 (37%) were on mycophenolate mofetil (MMF). 
The most frequent vaccine type was mRNA (n = 10, 
53%), and the remaining patients received inactivated 
(n  =  5, 26%) and viral vector vaccines (n  =  4, 21%). 
Among those who received a single vaccine dose, 
the median time from the vaccination to infection 
was 2 weeks (range 1- 5), and for those who received 
two doses, the median time from the second vaccine 
dose to infection was 3.5 weeks (range 2- 12). Most 
(n  =  13, 68%) patients had respiratory symptoms at 
diagnosis, and 1 (5%) had no respiratory or GI symp-
toms (Table 3). There were 6 hospitalizations (32%), 
including 3 (16%) resulting in mechanical ventila-
tion and ICU admission and 2 (11%) resulting in 
death. Deaths were from COVID- 19 lung disease 
in 1 patient and cardiogenic shock in 1 patient. Of 
note, all three cases of severe COVID- 19 occurred 
taBle 3. symptoms, HospitaliZation, iCu aDmission, inVasiVe Ventilation, anD DeatH By 
liVeR Disease anD VaCCination status
















GI and/or respiratory 
symptoms (n, %)
13 (62%) 172 (76%) 12 (63%) 118 (74%) 17 (89%) 68 (88%)
Hospitalization (n, %) 7 (33%) 162 (72%) 7 (37%) 118 (74%) 6 (32%) 33 (43%)
ICU admission (n, %) 1 (5%) 20 (9%) 1 (5%) 15 (9%) 3 (16%)* 7 (9%)
Invasive ventilation (n, %) 0 (0%) 12 (5%) 0 (0%) 9 (6%) 3 (16%)* 9 (12%)
Death (n, %) 0 (0%) 18 (8%) 0 (0%) 15 (9%) 2 (11%)* 6 (8%)
*All among patients with a single dose within 1- 2 weeks of SARS- CoV- 2 diagnosis.
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in patients who had a single vaccine dose within the 
last 1- 2 weeks (i.e., not fully vaccinated). Among fully 
vaccinated LT recipients (n = 5), there were 2 hospi-
talizations and 0 ICU admissions or deaths.
There were 77 unvaccinated LT recipients with lab- 
confirmed COVID- 19 (median age  =  53 years, 55% 
male, median time from transplant  =  6 years [range 
<1- 31 years], 48% on tacrolimus monotherapy/29% 
on prednisone/22% on MMF). Respiratory symp-
toms were reported in 29 (38%), GI symptoms in 3 
(4%), both GI/respiratory symptoms in 36 (47%), and 
neither respiratory nor GI symptoms in 8 (10%). Of 
these unvaccinated LT recipients, 33 (43%) were hos-
pitalized, 7 (9%) were admitted to the ICU, 9 (12%) 
required mechanical ventilation, and 6 (8%) died, all 
from COVID- 19 lung disease (Table 3).
Discussion
In the general population, SARS- CoV- 2 vacci-
nation has demonstrated excellent safety and effi-
cacy, resulting in a robust immune response and 
significantly reduced risks of COVID- 19 infection 
and complications.(16) As we have previously shown, 
patients with decompensated cirrhosis have increased 
risks of COVID- 19 complications resulting in ICU 
admission and death.(2) Given the potential for higher 
risks of COVID- 19 in CLD and LT recipients, guide-
lines strongly recommend vaccination in patients with 
liver diseases.(9- 11) In patients with CLD and prior 
LT, there is a lingering concern of low vaccine immu-
nogenicity, given underlying immune dysfunction.(12) 
This case series adds to recently published literature 
on breakthrough infections in transplant recipients,(26) 
demonstrating the potential for breakthrough SARS- 
CoV- 2 infections in patients with CLD and LT 
recipients. Yet, reassuringly, among patients who were 
fully vaccinated, there were no cases resulting in ICU 
admission, invasive ventilation, or death. Furthermore, 
among patients with CLD and cirrhosis, rates of hos-
pitalization, ICU admission, invasive ventilation, and 
death were numerically lower among patients who 
had received at least one vaccine dose compared with 
those who were unvaccinated. These findings are con-
sistent with recently published papers reporting that 
SARS- CoV- 2 vaccination reduces severe disease in 
patients with cirrhosis(27) and solid organ transplant 
recipients.(28)
Data on COVID- 19 vaccine response primary 
consist of reports of postvaccination antibody titers 
in LT recipients.(24) Antibody titers are not the only 
correlate of protection against SARS- CoV- 2 infec-
tion and may not be a sufficient measure of protec-
tion against COVID- 19 in patients with CLD and 
LT recipients. It may be that antibodies help prevent 
infections, which could explain breakthrough infec-
tions in our series. However, T- cell responses, which 
may be preserved and sufficient in patients with 
CLD and LT recipients, might help attenuate the 
COVID- 19 disease course. This could underlie the 
low rates of ICU admission, mechanical ventilation, 
and death in patients with CLD who received the full 
COVID- 19 vaccine series in this data set. Supporting 
these observations, a recent report suggests that heart 
and liver transplant recipients develop adequate 
humoral or cellular responses to an mRNA vac-
cine.(29) Postvaccination T- cell responses in patients 
with CLD have yet to be fully characterized.
The few cases of severe COVID- 19 resulting 
in ICU admission and death reported in this series 
occurred after a single dose of SARS- CoV- 2 vacci-
nation and were diagnosed within 1- 2 weeks after 
the vaccine dose. SARS- CoV- 2 immunity continues 
to improve beyond 2 weeks of the first mRNA vac-
cine dose and increases further after a second dose.(30) 
It is also possible that some of these patients had 
SARS- CoV- 2 infection at the time of vaccination. 
These data are important to inform patients on the 
need to complete the SARS- CoV- 2 vaccination series 
and use other recommended strategies to prevent 
SARS- CoV- 2 acquisition.
Among fully vaccinated patients, there were no 
cases of COVID- 19 resulting in ICU admission, 
mechanical ventilation or death, which should pro-
vide reassurance to patients and providers. However, 
there were some cases in our series of liver- related 
decompensation events in fully vaccinated individuals, 
and the potential for breakthrough cases among an 
immunosuppressed population raises questions about 
improved strategies of protection against COVID- 19 
in vulnerable populations. There has been interest 
in providing a booster dose to immunosuppressed 
patients, who may not mount a robust immune 
response. In a recent case series of vaccinated trans-
plant recipients, a third of patients with negative anti-
body titers after two doses had increased titers after 
a third SARS- CoV- 2 vaccination dose.(31) However, 
Hepatology CommuniCations, month 2021MOON ET AL.
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a large proportion of patients had persistently low or 
negative anti- spike antibody titers after a third booster 
dose. Until more data are available on the benefits of 
this strategy, this suggests that precautions including 
social distancing and masking should remain in place 
for patients at the highest risk of severe COVID- 19, 
including those with decompensated cirrhosis.(2)
This study is strengthened by its large, international, 
diverse patient data set. Additionally, the use of clini-
cian reporting minimizes the risk of misclassification of 
liver disease, vaccination details, and COVID- 19 out-
comes. However, the findings of this study have to be 
interpreted in the context of potential limitations. First, 
this cohort may be subject to selection bias inherent in 
registry studies, potentially resulting in an overrepre-
sentation of patients with severe COVID- 19. Second, 
this study design does not allow for the identification 
of patients with liver disease who were vaccinated but 
did not test positive for SARS- CoV- 2. Therefore, while 
these data demonstrate the potential for breakthrough 
infections, we are unable to determine the rates of 
COVID- 19 infections among vaccinated patients with 
liver disease. Third, as a comparison population, we 
included cases of SARS- CoV- 2 among unvaccinated 
patients with CLD and liver transplant recipients. 
While these cases were submitted to registries during 
an identical time period to vaccinated cases (March 5, 
2021, to July 22, 2021), it remains possible that some of 
the infections among unvaccinated individuals occurred 
before this time (such as before vaccines were available) 
and were logged after some delay. Finally, we were not 
able to adjust for potential center- specific or region- 
specific differences in the management of COVID- 19, 
which could influence hospitalization rates, ICU esca-
lation decisions, and outcomes.
In summary, this case series demonstrates the 
potential for breakthrough COVID- 19 infec-
tions among patients with CLD and LT recipients. 
Although some fully vaccinated patients were hos-
pitalized, reassuringly, COVID- 19 resulting in ICU 
admission or death was limited to patients who had 
received a recent, single SARS- CoV- 2 dose. These 
data reinforce the existing guidelines recommending 
COVID- 19 vaccination for patients with CLD and 
LT recipients. However, well- established strategies for 
COVID- 19 prevention, including physical distancing 
and masking, should be considered even for vacci-
nated patients with CLD and LT recipients. Given 
the remaining unknowns, ongoing research in these 
populations on postvaccine immune response and 
strategies such as booster doses will be important.
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